CoChat

Routinely collected data for randomized trials: promises, barriers, and implications

Open access
Mc Cord, Kimberly A., Al-Shahi Salman, Rustam, Treweek, Shaun, Gardner, Heidi, Strech, Daniel, Whiteley, William, Ioannidis, John P. A., Hemkens, Lars G. · 2018 · Trials
Cited by 148

The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.

Abstract

BACKGROUND: Routinely collected health data (RCD) are increasingly used for randomized controlled trials (RCTs). This can provide three major benefits: increasing value through better feasibility (reducing costs, time, and resources), expanding the research agenda (performing trials for research questions otherwise not amenable to trials), and offering novel design and data collection options (e.g., point-of-care trials and other designs directly embedded in routine care). However, numerous hurdles and barriers must be considered pertaining to regulatory, ethical, and data aspects, as well as the costs of setting up the RCD infrastructure. Methodological considerations may be different from those in traditional RCTs: RCD are often collected by individuals not involved in the study and who are therefore blinded to the allocation of trial participants. Another consideration is that RCD trials may lead to greater misclassification biases or dilution effects, although these may be offset by randomization and larger sample sizes. Finally, valuable insights into external validity may be provided when using RCD because it allows pragmatic trials to be performed. METHODS: We provide an overview of the promises, challenges, and potential barriers, methodological implications, and research needs regarding RCD for RCTs. RESULTS: RCD have substantial potential for improving the conduct and reducing the costs of RCTs, but a multidisciplinary approach is essential to address emerging practical barriers and methodological implications. CONCLUSIONS: Future research should be directed toward such issues and specifically focus on data quality validation, alternative research designs and how they affect outcome assessment, and aspects of reporting and transparency.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/s13063-017-2394-5

Cites

8 of 8 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 8 references

Research works printed but not linked: 34

  1. Mathes T, Buehn S, Prengel P, Pieper D. Registry-based randomized controlled trials merged the strength of randomized controlled trials and observational studies and give rise to more pragmatic trials. J Clin Epidemiol. doi: https://doi.org/10.1016/j.jclinepi.2017.09.017 . · DOI
  2. Lund LH, Oldgren J, James S. Registry-based pragmatic trials in heart failure: current experience and future directions. Curr Heart Fail Rep. 2017;14(2):59–70. · DOI · Paper page
  3. Li G, Sajobi TT, Menon BK, et al. Registry-based randomized controlled trials – what are the advantages, challenges, and areas for future research? J Clin Epidemiol. 2016;80(Suppl C):16–24. · DOI · Paper page
  4. Choudhry NK. Randomized, controlled trials in health insurance systems. N Engl J Med. 2017;377(10):957–64. · DOI
  5. Zuidgeest MGP, Goetz I, Groenwold RHH, Irving E, van Thiel G, Grobbee DE. Series: Pragmatic trials and real world evidence. Paper 1: Introduction. J Clin Epidemiol. 2017;88:7–13. · DOI · Paper page
  6. Meinecke AK, Welsing P, Kafatos G, Burke D, Trelle S, Kubin M, Nachbaur G, Egger M, Zuidgeest M. work package 3 of the GetReal consortium. Series: Pragmatic trials and real world evidence: Paper 8. Data collection and management. J Clin Epidemiol. 2017;91:13–22. doi: https://doi.org/10.1016/j.jclinepi.2017.07.003 . · DOI
  7. Kim SY, Miller FG. Informed consent for pragmatic trials—the integrated consent model. N Engl J Med. 2014;370(8):769–72. · DOI · Paper page
  8. Hemkens LG, Contopoulos-Ioannidis DG, Ioannidis JP. Routinely collected data and comparative effectiveness evidence: promises and limitations. CMAJ. 2016;188(8):E158–64. · DOI · Paper page
  9. Kasenda B, von Elm EB, You J, et al. Learning from failure - rationale and design for a study about discontinuation of randomized trials (DISCO study). BMC Med Res Methodol. 2012;12:131. · DOI · Paper page
  10. Rao JN, Cassia LJS. Ethics of undisclosed payments to doctors recruiting patients in clinical trials. BMJ. 2002;325(7354):36–7. · DOI
  11. Aung T, Haynes R, Barton J, et al. Cost-effective recruitment methods for a large randomised trial in people with diabetes: A Study of Cardiovascular Events iN Diabetes (ASCEND). Trials. 2016;17(1):286. · DOI · Paper page
  12. Gliklich RE, Dreyer NA, Leavy MB. Rare disease registries. In: Registries for evaluating patient outcomes: a user’s guide. 3rd ed. Rockville, MD: Agency for Healthcare Research and Quality; 2014. p. 113–25.
  13. Bargaje C. Good documentation practice in clinical research. Perspect Clin Res. 2011;2(2):59–63. · doi:10.4103/2229-3485.80368
  14. van Engelen B. Cognitive behaviour therapy plus aerobic exercise training to increase activity in patients with myotonic dystrophy type 1 (DM1) compared to usual care (OPTIMISTIC): study protocol for randomised controlled trial. Trials. 2015;16:224. · DOI
  15. Ioannidis JA. Mega-trials for blockbusters. JAMA. 2013;309(3):239–40. · DOI
  16. Ramsberg J, Neovius M. Register or electronic health records enriched randomized pragmatic trials: the future of clinical effectiveness and cost-effectiveness trials? Nordic J Health Econ. 2015;3(1):1–15. doi: https://doi.org/10.5617/njhe.1386 . · DOI
  17. Antman EM, Bierer BE. Standards for clinical research: keeping pace with the technology of the future. Circulation. 2016;133(9):823–5. · DOI
  18. Hemkens LG, Contopoulos-Ioannidis DG, Ioannidis JP. Concordance of effects of medical interventions on hospital admission and readmission rates with effects on mortality. CMAJ. 2013;185(18):E827–37. · DOI
  19. Jensen RE, Snyder CF, Abernethy AP, et al. Review of electronic patient-reported outcomes systems used in cancer clinical care. J Oncol Pract. 2014;10(4):e215–22. · DOI · Paper page
  20. Hemkens LG, Saccilotto R, Reyes SL, et al. Personalized prescription feedback using routinely collected data to reduce antibiotic use in primary care: a randomized clinical trial. JAMA Intern Med. 2017;177(2):176–83. · DOI
  21. Schmidt C. Cancer: reshaping the cancer clinic. Nature. 2015;527(7576):S10–1. · DOI
  22. Nuffield Council on Bioethics. The collection, linking and use of data in biomedical research and health care: ethical issues. London: Nuffield Council on Bioethics; 2015. http://nuffieldbioethics.org/project/biological-health-data/.
  23. Faden R, Kass N, Whicher D, Stewart W, Tunis S. Ethics and informed consent for comparative effectiveness research with prospective electronic clinical data. Med Care. 2013;51(8 Suppl 3):S53–7. · DOI
  24. Nayak RK, Wendler D, Miller FG, Kim SY. Pragmatic randomized trials without standard informed consent? A national survey. Ann Intern Med. 2015;163(5):356–64. · DOI
  25. Cho MK, Magnus D, Constantine M, et al. Attitudes toward risk and informed consent for research on medical practices: a cross-sectional survey. Ann Intern Med. 2015;162(10):690–6. · DOI
  26. Strech D, Bein S, Brumhard M, et al. A template for broad consent in biobank research: results and explanation of an evidence and consensus-based development process. Eur J Med Genet. 2016;59(6–7):295–309. · DOI
  27. Beskow LM, Friedman JY, Hardy NC, Lin L, Weinfurt KP. Developing a simplified consent form for biobanking. PLoS One. 2010;5(10):e13302. · DOI · Paper page
  28. Lasko TA, Vinterbo SA. Spectral anonymization of data. IEEE Trans Knowl Data Eng. 2010;22(3):437–46. · DOI
  29. Califf RM, Sanderson I, Miranda ML. The future of cardiovascular clinical research: informatics, clinical investigators, and community engagement. JAMA. 2012;308(17):1747–8. · DOI
  30. Bhise V, Meyer AND, Singh H, et al. Errors in diagnosis of spinal epidural abscesses in the era of electronic health records. Am J Med. 2017;130(8):975–81. · DOI
  31. Jacob C, Meise D, Mittendorf T, Braun S. The use of real world evidence to support market access of medical devices – implications for the German setting [abstract]. Value Health. 2015;18(7):A372. · doi:10.1016/j.jval.2015.09.759
  32. Frobert O, Lagerqvist B, Olivecrona GK, et al. Thrombus aspiration during ST-segment elevation myocardial infarction. N Engl J Med. 2013;369(17):1587–97. · DOI · Paper page
  33. Emilsson L, Lindahl B, Koster M, Lambe M, Ludvigsson JF. Review of 103 Swedish healthcare quality registries. J Intern Med. 2015;277(1):94–136. · DOI · Paper page
  34. Bohm ER, Dunbar MJ, Bourne R. The Canadian Joint Replacement Registry—what have we learned? Acta Orthop. 2010;81(1):119–21. · doi:10.3109/17453671003685467

Cited by

See all 148

Metadata

Authors
Mc Cord, K. A., Al-Shahi Salman, R., Treweek, S., Gardner, H., Strech, D., Whiteley, W., Ioannidis, J. P. A., & Hemkens, L. G.
Venue
Trials
Published
2018-01-11
Volume
19
Issue
1
Pages
29-29
ISSN
1745-6215 (ISSN-L)
OpenAlex
W2783288989
Cited by
148
References
8
FWCI
13.30
Type
journal article
Language
en
Open access
gold
Funders
  • Laura and John Arnold Foundation
  • Stiftung Institut für klinische Epidemiologie

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Routinely collected data for randomized trials: promises, barriers, and implications. https://app.cochat.ai/papers/10.1186/s13063-017-2394-5
The paper
Mc Cord, K. A., Al-Shahi Salman, R., Treweek, S., Gardner, H., Strech, D., Whiteley, W., Ioannidis, J. P. A., & Hemkens, L. G. (2018). Routinely collected data for randomized trials: promises, barriers, and implications. Trials. https://doi.org/10.1186/s13063-017-2394-5

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.